Immuneering Corporation
IMRX
$6.74
$0.050.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.50M | 16.01M | 15.97M | 16.08M | 16.77M |
| Depreciation & Amortization | 29.20K | 29.20K | 29.20K | 29.20K | 29.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.18M | 64.07M | 64.23M | 64.07M | 61.82M |
| Operating Income | -64.18M | -64.07M | -64.23M | -64.07M | -61.82M |
| Income Before Tax | -62.50M | -62.13M | -61.77M | -61.04M | -58.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.50 | -62.13 | -61.77 | -61.04 | -58.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.50M | -62.13M | -61.77M | -61.04M | -58.07M |
| EBIT | -64.18M | -64.07M | -64.23M | -64.07M | -61.82M |
| EBITDA | -63.82M | -63.70M | -63.85M | -63.69M | -61.43M |
| EPS Basic | -1.78 | -1.90 | -1.97 | -2.03 | -1.97 |
| Normalized Basic EPS | -1.11 | -1.18 | -1.23 | -1.27 | -1.23 |
| EPS Diluted | -1.78 | -1.90 | -1.97 | -2.03 | -1.97 |
| Normalized Diluted EPS | -1.11 | -1.18 | -1.23 | -1.27 | -1.23 |
| Average Basic Shares Outstanding | 142.24M | 132.41M | 126.08M | 119.92M | 118.14M |
| Average Diluted Shares Outstanding | 142.24M | 132.41M | 126.08M | 119.92M | 118.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |